EFFICACY OF COMBINATION FLUDARABINE AND ALEMTUZUMAB IN PATIENTS WITH RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

被引：0
|
作者：
Zagoskina, T. [1 ]
Zotina, E. [1 ]
Malykh, O. [1 ]
机构：
[1] Kirov Res Inst Hematol & Blood Transfus, Kirov, Russia
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0752
引用
收藏
页码：305 / 305
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia
    Elter, Thomas
    Kilp, Julia
    Borchmann, Peter
    Schulz, Holger
    Hallek, Michael
    Engert, Andreas
    Haematologica-The Hematology Journal, 2009, 94 (01): : 150 - 152
  • [2] Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia
    Elter, T.
    James, R.
    Busch, R.
    Winkler, D.
    Ritgen, M.
    Boettcher, S.
    Kahl, C.
    Gassmann, W.
    Stauch, M.
    Hasan, I.
    Staib, P.
    Fischer, K.
    Fink, A-M
    Bahlo, J.
    Buehler, A.
    Doehner, H.
    Wendtner, C-M
    Stilgenbauer, S.
    Engert, A.
    Hallek, M.
    LEUKEMIA, 2012, 26 (12) : 2549 - 2552
  • [3] Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia
    T Elter
    R James
    R Busch
    D Winkler
    M Ritgen
    S Böttcher
    C Kahl
    W Gassmann
    M Stauch
    I Hasan
    P Staib
    K Fischer
    A-M Fink
    J Bahlo
    A Bühler
    H Döhner
    C-M Wendtner
    S Stilgenbauer
    A Engert
    M Hallek
    Leukemia, 2012, 26 : 2549 - 2552
  • [4] Combination of fludarabine (FAMP) cyclophosphamide (CTX) and alemtuzumab for patients with relapsed chronic lymphocytic leukemia (CLL).
    Tedeschi, A
    Montillo, M
    Miqueleiz, S
    Draisci, M
    Ricci, F
    Scarpati, B
    Mura, ME
    Crugnola, M
    Morra, E
    BLOOD, 2005, 106 (11) : 341B - 341B
  • [5] Economic Analysis of Alemtuzumab in Fludarabine-Refractory and Relapsed Chronic Lymphocytic Leukemia in Canada
    Isogai, Pierre K.
    Cheung, Matthew
    Mittmann, Nicole
    BLOOD, 2008, 112 (11) : 827 - 827
  • [6] Efficacy and Safety of Ofatumumab in Patients with Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (03): : 200 - 202
  • [7] Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients
    Montillo, Marco
    Tedeschi, Alessandra
    Gaidano, Gianluca
    Coscia, Marta
    Petrizzi, Valeria Belsito
    Orlandi, Ester
    Cascavilla, Nicola
    Ghia, Paolo
    Motta, Marina
    Gallamini, Andrea
    Frustaci, Anna Maria
    Rossi, Davide
    De Paoli, Lorenzo
    Nichelatti, Michele
    Morra, Enrica
    Massaia, Massimo
    HAEMATOLOGICA, 2014, 99 (09) : E159 - E161
  • [8] Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia
    McCune, SL
    Gockerman, JP
    Moore, JO
    Decastro, CM
    Bass, AJ
    Chao, NJ
    Long, GD
    Vredenburgh, JJ
    Gasparetto, C
    Adams, D
    Payne, N
    Rizzieri, DA
    LEUKEMIA & LYMPHOMA, 2002, 43 (05) : 1007 - 1011
  • [9] Alemtuzumab Use In Relapsed and Refractory Chronic Lymphocytic Leukemia
    Arnason, Jon E.
    Brown, Jennifer R.
    HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM, 2011, : 119 - 120
  • [10] EFFICACY OF THE COMBINATION OF BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
    Zagoskina, T.
    Zotina, E.
    Ovsepyan, V.
    Shardakov, V.
    HAEMATOLOGICA, 2014, 99 : 591 - 591
12345